Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

720 ARTÍCULOS , VIENDO DEL 646 AL 660

Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities

Hardy J, Schott JM.

Neurology. 2024 Feb 13;102(3):e208096. doi: 10.1212/WNL.0000000000208096. Epub 2023 Dec 28.

Ginsenoside Rg1, lights up the way for the potential prevention of Alzheimer's disease due to its therapeutic effects on the drug-controllable risk factors of Alzheimer's disease

Wu JJ, Zhang L, Liu D, Xia J, Yang Y, Tang F, Chen L, Ao H, Peng C.

J Ethnopharmacol. 2024 Jan 10;318(Pt B):116955. doi: 10.1016/j.jep.2023.116955. Epub 2023 Aug 1.

Effects of DHA on cognitive dysfunction in aging and Alzheimer's disease: The mediating roles of ApoE

Zhang X, Yuan T, Chen X, Liu X, Hu J, Liu Z.

Prog Lipid Res. 2024 Jan;93:101256. doi: 10.1016/j.plipres.2023.101256. Epub 2023 Oct 27.

Hypertension & dementia: Pathophysiology & potential utility of antihypertensives in reducing disease burden

Lyon M, Fullerton JL, Kennedy S, Work LM.

Pharmacol Ther. 2024 Jan;253:108575. doi: 10.1016/j.pharmthera.2023.108575. Epub 2023 Dec 3.

Longitudinal Cognitive Decline in Alzheimer Disease Prevention Trials: A Test of Time

Castilhos RM, Snitz BE.

Neurology. 2024 Jan 23;102(2):e208067. doi: 10.1212/WNL.0000000000208067. Epub 2023 Dec 26.

Subcellular proteomics insights into Alzheimer's disease development

Liang Z, Zhuang H, Cao X, Ma G, Shen L.

Proteomics Clin Appl. 2024 May;18(3):e2200112. doi: 10.1002/prca.202200112. Epub 2023 Aug 31.

Anti-amyloid antibody treatments for Alzheimer's disease

Perneczky R, Dom G, Chan A, Falkai P, Bassetti C.

Eur J Neurol. 2024 Feb;31(2):e16049. doi: 10.1111/ene.16049. Epub 2023 Sep 11.

Neprilysin inhibitors and risk of Alzheimer's disease: A future perspective

Ali NH, Al-Kuraishy HM, Al-Gareeb AI, Alnaaim SA, Alexiou A, Papadakis M, Khalifa AA, Saad HM, Batiha GE.

J Cell Mol Med. 2024 Jan;28(2):e17993. doi: 10.1111/jcmm.17993. Epub 2023 Oct 17.

Comparative methods for quantifying plasma biomarkers in Alzheimer's disease: Implications for the next frontier in cerebral amyloid angiopathy diagnostics

Muir RT, Ismail Z, Black SE, Smith EE.

Alzheimers Dement. 2024 Feb;20(2):1436-1458. doi: 10.1002/alz.13510. Epub 2023 Oct 31.

Comparison of CSF and plasma NfL and pNfH for Alzheimer's disease diagnosis: a memory clinic study

Vrillon A, Ashton NJ, Karikari TK, Götze K, Cognat E, Dumurgier J, Lilamand M, Zetterberg H, Blennow K, Paquet C.

J Neurol. 2024 Mar;271(3):1297-1310. doi: 10.1007/s00415-023-12066-6. Epub 2023 Nov 11.

Clusterin is a Potential Therapeutic Target in Alzheimer's Disease

Palihati N, Tang Y, Yin Y, Yu D, Liu G, Quan Z, Ni J, Yan Y, Qing H.

Mol Neurobiol. 2024 Jul;61(7):3836-3850. doi: 10.1007/s12035-023-03801-1. Epub 2023 Nov 29.

Therapeutic implications of glycogen synthase kinase-3β in Alzheimer's disease: a novel therapeutic target

Mandlik DS, Mandlik SK, S A.

Int J Neurosci. 2024 Jun;134(6):603-619. doi: 10.1080/00207454.2022.2130297. Epub 2022 Oct 10.

Opportunities and challenges for the development of M(1) muscarinic receptor positive allosteric modulators in the treatment for neurocognitive deficits

Nguyen HTM, van der Westhuizen ET, Langmead CJ, Tobin AB, Sexton PM, Christopoulos A, Valant C.

Br J Pharmacol. 2024 Jul;181(14):2114-2142. doi: 10.1111/bph.15982. Epub 2022 Dec 4.

Study rationale and baseline data for pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's dementia (THC-AD)

Cohen LM, Ash E, Outen JD, Vandrey R, Amjad H, Agronin M, Burhanullah MH, Walsh P, Wilkins JM, Leoutsakos JM, Nowrangi MA, Harper D, Rosenberg PB, Forester BP.

Int Psychogeriatr. 2024 Dec;36(12):1245-1250. doi: 10.1017/S1041610221001150. Epub 2021 Oct 11.

Role of uric acid in neurodegenerative diseases, focusing on Alzheimer and Parkinson disease: A new perspective

Alrouji M, Al-Kuraishy HM, Al-Gareeb AI, Alshammari MS, Alexiou A, Papadakis M, Bahaa MM, Batiha GE.

Neuropsychopharmacol Rep. 2024 Sep;44(3):639-649. doi: 10.1002/npr2.12445. Epub 2024 Jul 29.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias